The Diagnostics kits of methylated genes of lung cancer are relied on a blood-based test and combine with proprietary epigenomics ctDNA methylation biomarkers for diagnosis of lung cancer, also known as abnormal gene epigenetic modification. Lung cancer diagnostic kits as an auxiliary screening technique can alleviate and avoid patient anxiety during times of uncertain results, assist the doctors with a clinical diagnosis of diseases, providing doctors with a fast, accurate, and reliable method to diagnose cancer.
The Diagnostics kits can be used for lung cancer screening by detecting abnormal methylation levels of ctDNA. It can predict the development of cancer and monitor cancer metastasis and recurrence.
The Diagnostics kits can be used at various stages of cancer development.
*Disclaimer:
LEPU Medical applied methlylation markers to auxiliary diagnose lung cancer.[3][4]
Picture shown for illustrative purposes only.
Lung cancer is the 2nd most common cancer and the most deadly cancer worldwide. According to Global Cancer Statistics 2020, the incidence rate of lung cancer is about 11.4%[1].
Lung cancer is cancer with the greatest economic impact and the greatest number of years of life lost worldwide[2].
Performance of Diagnostic Kit for Methylated Genes of Lung Cancer
Lepu Medical has developed the advanced MSP+MethylLight technology for auxiliary diagnosis of cancer.
Population Groups Recommended for Screening
Smoking history (including current or former smokers) or smoke exposure (passive smoking).
Male and female aged 40 and above.
Been diagnosed with a pulmonary nodule.